O'Loughlin KG - Search Results

1

In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus.

Dyall J, Johnson JC, Hart BJ, Postnikova E, Cong Y, Zhou H, Gerhardt DM, Michelotti J, Honko AN, Kern S, DeWald LE, O'Loughlin KG, Green CE, Mirsalis JC, Bennett RS, Olinger GG Jr, Jahrling PB, Hensley LE. Dyall J, et al. Among authors: o loughlin kg. J Infect Dis. 2018 Nov 22;218(suppl_5):S592-S596. doi: 10.1093/infdis/jiy345. J Infect Dis. 2018. PMID: 30016444 Free PMC article.

2

Radiation-induced point mutations, deletions and micronuclei in lacI transgenic mice.

Winegar RA, Lutze LH, Hamer JD, O'Loughlin KG, Mirsalis JC. Winegar RA, et al. Among authors: o loughlin kg. Mutat Res. 1994 Jun 1;307(2):479-87. doi: 10.1016/0027-5107(94)90258-5. Mutat Res. 1994. PMID: 7514721

3

Induction of hepatic mutations in lacI transgenic mice.

Mirsalis JC, Provost GS, Matthews CD, Hamner RT, Schindler JE, O'Loughlin KG, MacGregor JT, Short JM. Mirsalis JC, et al. Among authors: o loughlin kg. Mutagenesis. 1993 May;8(3):265-71. doi: 10.1093/mutage/8.3.265. Mutagenesis. 1993. PMID: 8332090

4

Chromium (VI) at plausible drinking water concentrations is not genotoxic in the in vivo bone marrow micronucleus or liver unscheduled DNA synthesis assays.

Mirsalis JC, Hamilton CM, O'Loughlin KG, Paustenbach DJ, Kerger BD, Patierno S. Mirsalis JC, et al. Among authors: o loughlin kg. Environ Mol Mutagen. 1996;28(1):60-3. doi: 10.1002/(SICI)1098-2280(1996)28:1<60::AID-EM9>3.0.CO;2-I. Environ Mol Mutagen. 1996. PMID: 8698048 No abstract available.

5

Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate.

Coughlin JE, Pandey RK, Padmanabhan S, O'Loughlin KG, Marquis J, Green CE, Mirsalis JC, Iyer RP. Coughlin JE, et al. Among authors: o loughlin kg. Drug Metab Dispos. 2012 May;40(5):970-81. doi: 10.1124/dmd.111.044446. Epub 2012 Feb 10. Drug Metab Dispos. 2012. PMID: 22328581 Free PMC article.

6

Formulation approaches to improving the delivery of an antiviral drug with activity against seasonal flu.

Sammeta SM, Wang L, Mutyam SK, O'Loughlin K, Green CE, Werner MH, Kelly T, Shankar GN. Sammeta SM, et al. Pharm Dev Technol. 2015 Mar;20(2):169-75. doi: 10.3109/10837450.2013.852574. Epub 2013 Nov 13. Pharm Dev Technol. 2015. PMID: 24218989

7

Pharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor.

Nair V, Okello M, Mishra S, Mirsalis J, O'Loughlin K, Zhong Y. Nair V, et al. Antiviral Res. 2014 Aug;108:25-9. doi: 10.1016/j.antiviral.2014.05.001. Epub 2014 May 10. Antiviral Res. 2014. PMID: 24821255 Free PMC article.

8

(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function.

Paul RK, Singh NS, Khadeer M, Moaddel R, Sanghvi M, Green CE, O'Loughlin K, Torjman MC, Bernier M, Wainer IW. Paul RK, et al. Anesthesiology. 2014 Jul;121(1):149-59. doi: 10.1097/ALN.0000000000000285. Anesthesiology. 2014. PMID: 24936922 Free PMC article.

9

Pharmacokinetics and Metabolism of 4R-Cembranoid.

Vélez-Carrasco W, Green CE, Catz P, Furimsky A, O'Loughlin K, Eterović VA, Ferchmin PA. Vélez-Carrasco W, et al. PLoS One. 2015 Mar 26;10(3):e0121540. doi: 10.1371/journal.pone.0121540. eCollection 2015. PLoS One. 2015. PMID: 25811857 Free PMC article.

10

The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats.

Moaddel R, Sanghvi M, Dossou KS, Ramamoorthy A, Green C, Bupp J, Swezey R, O'Loughlin K, Wainer IW. Moaddel R, et al. Pharmacol Res Perspect. 2015 Aug;3(4):e00157. doi: 10.1002/prp2.157. Epub 2015 Jun 22. Pharmacol Res Perspect. 2015. PMID: 26171236 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page